Correction: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody

The correction does not alter the scientific outcome since the result about the colocalization analysis of VEGF-A and GFAP in control and oxaliplatin-treated mice did not require the use of DAPI channel. The correction does not alter the scientific outcome since the result about the colocalization analysis of VEGF-A and GFAP in control and oxaliplatin-treated mice did not require the use of DAPI channel. Incorrect Fig. 6 Fig. 6 figure 1 VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c). A Bonferroni’s significant difference procedure was used as post-hoc comparison Full size image Correct Fig. 6 Fig. 6 figure 2 VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c).